Home › NDC Lookup › J-codes › Q2050
Q2050

Q2050 – Injection, doxorubicin hydrochloride, liposomal, not otherwise specified · NDC Crosswalk & Billing Units

HCPCS Level II Q-code · Medicare Part B drug billing
Q-code ● 38 NDCs crosswalked per 10 MG $116.605/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 Q2050 summary

Q2050 is a HCPCS Level II Q-code used to bill doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with Q2050: Doxil*, Doxil, Doxorubicin Hydrochloride

Code Q2050 Billing unit 10 MG Payment limit $116.605/unit NDC-Crosswalk 38 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeQ2050
DescriptorInjection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Billing unit10 MG
Payment limit / unit$116.605
Est. ASP / unit$110.005 est.
Mapped NDCs38
Data periodQ3 2026
Last updated2026-08-20

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$116.605
Est. ASP / unit
$110.005 est.
Est. after 2% sequester
$114.273
HCPCS dosage
10 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2013-07-01
Date added2013-07-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of Q2050 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under Q2050 WITH EST. MEDICARE PAY

38 NDCs map to Q2050. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($116.605/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00338-0063-01 DOXIL doxorubicin hydrochloride 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Baxter 1 VIAL, SINGLE-USE in 1 CARTON (0338-0063-... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
00338-0067-01 DOXIL doxorubicin hydrochloride 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Baxter 1 VIAL, SINGLE-USE in 1 CARTON (0338-0067-... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
00338-9665-01 DOXIL doxorubicin hydrochloride 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Baxter 1 VIAL, SINGLE-DOSE in 1 CARTON (0338-9665... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
00338-9667-01 DOXIL doxorubicin hydrochloride 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Baxter 1 VIAL, SINGLE-DOSE in 1 CARTON (0338-9667... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
16714-0742-01 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL NorthStar 1 VIAL, SINGLE-DOSE in 1 CARTON (16714-742... 2 mg/mL 2 $233.21 — Obsolete CMS + PDAC
16714-0856-01 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL NorthStar 1 VIAL, SINGLE-DOSE in 1 CARTON (16714-856... 2 mg/mL 5 $583.03 — Obsolete CMS + PDAC
25021-0263-10 Doxorubicin Hydrochloride Liposome 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Sagent 1 VIAL in 1 CARTON (25021-263-10) / 10 mL... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
25021-0263-25 Doxorubicin Hydrochloride Liposome 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Sagent 1 VIAL in 1 CARTON (25021-263-25) / 25 mL... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
43598-0283-35 Doxorubicin HCl, Liposomal Dr. — — 2 $233.21 — — CMS ASP
43598-0541-25 Doxorubicin HCl, Liposomal Dr. — — 5 $583.03 — — CMS ASP
43598-0682-35 Doxorubicin HCl, Liposomal Dr. — — 2 $233.21 — — CMS + PDAC
43598-0683-25 Doxorubicin HCl, Liposomal Dr. — — 5 $583.03 — — CMS + PDAC
47335-0049-40 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL Sun 1 VIAL, SINGLE-DOSE in 1 PACKAGE (47335-04... 2 mg/mL 2 $233.21 — ● Active CMS ASP
47335-0050-40 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL Sun 1 VIAL, SINGLE-DOSE in 1 PACKAGE (47335-05... 2 mg/mL 5 $583.03 — ● Active CMS ASP
68001-0345-26 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL BluePoint 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-345... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
68001-0345-36 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL BluePoint 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-345... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
68001-0492-36 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL BluePoint 1 VIAL, SINGLE-DOSE in 1 PACKAGE (68001-49... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
68001-0493-26 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL BluePoint 1 VIAL, SINGLE-DOSE in 1 PACKAGE (68001-49... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
68001-0629-26 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL BluePoint 1 VIAL, SINGLE-USE in 1 CARTON (68001-629-... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
68001-0629-36 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL BluePoint 1 VIAL, SINGLE-USE in 1 CARTON (68001-629-... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
70710-1530-01 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTABLE, LIPOSOMAL Zydus 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-153... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
70710-1531-01 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTABLE, LIPOSOMAL Zydus 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-153... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
70748-0339-01 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Lupin 1 VIAL, SINGLE-USE in 1 CARTON (70748-339-... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
70748-0340-01 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Lupin 1 VIAL, SINGLE-USE in 1 CARTON (70748-340-... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
72603-0103-01 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL NorthStar 1 VIAL, SINGLE-DOSE in 1 PACKAGE (72603-10... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
72603-0200-01 Doxorubicin Hydrochloride 2 mg/mL INJECTABLE, LIPOSOMAL NorthStar 1 VIAL, SINGLE-DOSE in 1 PACKAGE (72603-20... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
75907-0363-01 doxorubicin hydrochloride 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Dr. 1 VIAL, SINGLE-DOSE in 1 CARTON (75907-363... 2 mg/mL 2 $233.21 — ● Active CMS + PDAC
75907-0364-01 doxorubicin hydrochloride 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Dr. 1 VIAL, SINGLE-DOSE in 1 CARTON (75907-364... 2 mg/mL 5 $583.03 — ● Active CMS + PDAC
68001-0703-36 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTABLE, LIPOSOMAL BluePoint 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-703... 2 mg/mL 0.2 $23.32 — ● Active PDAC
68001-0704-26 DOXORUBICIN HYDROCHLORIDE 2 mg/mL INJECTABLE, LIPOSOMAL BluePoint 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-704... 2 mg/mL 0.2 $23.32 — ● Active PDAC
72603-0346-01 DOXORUBICIN HCL LIPOSOME 1X10ML;SDV 2 MG/1 ML Unknown — — 0.2 $23.32 — — PDAC
72603-0507-01 DOXORUBICIN HCL LIPOSOME 1X25ML;SDV 2 MG/1 ML Unknown — — 0.2 $23.32 — — PDAC
00574-0931-25 DOXORUBICIN HCL LIPOSOME (SDV,PF,LATEX-FREE) 2 MG/1 ML Unknown — — 0.2 $23.32 — — PDAC
00574-0930-10 DOXORUBICIN HCL LIPOSOME (SDV,PF,LATEX-FREE) 2 MG/1 ML Unknown — — 0.2 $23.32 — — PDAC
00338-0086-01 Doxorubicin Hydrochloride Liposome 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Baxter 1 VIAL, SINGLE-USE in 1 CARTON (0338-0086-... 2 mg/mL 0.2 $23.32 — ● Active PDAC
00338-0080-01 Doxorubicin Hydrochloride Liposome 2 mg/mL INJECTION, SUSPENSION, LIPOSOMAL Baxter 1 VIAL, SINGLE-USE in 1 CARTON (0338-0080-... 2 mg/mL 0.2 $23.32 — ● Active PDAC
59676-0966-02 DOXORUBICIN HCL LIPOSOME 2 MG/1 ML Unknown — — 0.2 $23.32 — — PDAC
59676-0966-01 DOXORUBICIN HCL LIPOSOME 2 MG/1 ML Unknown — — 0.2 $23.32 — — PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$3M
Claims
4,593
Beneficiaries
2,280
Spend / beneficiary
$1,315.66
Spend / claim
$653.11
Trend by period
Where Q2050 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #292 of 824
#287 NYVEPRIA Q5122 $3.1M #288 DEPO-MEDROL* J1010 $3.09M #289 ERIBULIN MESYLATE* J9179 $3.09M #290 OASIS ULTRA Q4124 $3.07M #291 THYROGEN J3240 $3.03M #292 DOXIL* Q2050 $3M #293 GRAFIX STRAVIX PRIME... Q4133 $2.95M #294 KENALOG-10* J3301 $2.92M #295 AVSOLA Q5121 $2.89M #296 YEZTUGO(J0738) J0738 $2.88M #297 MYCOPHENOLIC ACID* J7518 $2.87M
Total claims — #227 of 824
#222 EVEROLIMUS* J7527 5,068 #223 VECTIBIX J9303 5,053 #224 DACOGEN* J0894 4,978 #225 CUVITRU J1555 4,827 #226 TYSABRI J2323 4,821 #227 DOXIL* Q2050 4,593 #228 AMVUTTRA J0225 4,551 #229 OCREVUS J2350 4,531 #230 BENDEKA J9034 4,474 #231 DALBAVANCIN HCL* J0875 4,418 #232 FYLNETRA Q5130 4,408

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $3M 2,280 4,593 $1,315.66 $653.11
2025 (Q1-Q4) $15.53M 5,415 19,673 $2,868.38 $789.52
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$3.71M
Medicare paid
$3.01M
Submitted services
30,699
Denial rate
3.3%
Allowed / service
$125.03
Submitted charges
$32.88M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where Q2050 is utilized CMS · BY PROVIDER · 2024

Medicare Part B services for this code by the rendering provider's state — 888 services across 3 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.

📊 What bills under Q2050

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
doxorubicin hydrochloride 10
Doxorubicin Hydrochloride 8
DOXORUBICIN HYDROCHLORIDE 3
Doxorubicin Hydrochloride Liposome 2
NDC products by labeler
BluePoint Laboratories 6
Baxter Healthcare Company 4
NorthStar RxLLC 4
Baxter Healthcare Corporation 2
Zydus Pharmaceuticals USA Inc. 2
Lupin Pharmaceuticals, Inc. 2
Dr. Reddy's Laboratories Inc. 2
Sagent Pharmaceuticals 1

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
38 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ Q2050 billing FAQ

What is HCPCS code Q2050?
Q2050 is a HCPCS Level II Q-code used to bill Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for Q2050?
One unit of Q2050 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.
How many units of Q2050 should I bill?
Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for Q2050?
The Medicare Part B payment limit is $116.605 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $114.273 per unit. Payment limits are revised quarterly.
Which NDCs bill under Q2050?
38 NDCs currently map to Q2050 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean Q2050 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.